Fresh analysis indicates that people who discontinue popular GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who stop traditional diet and exercise regimens.
Findings released in a leading medical journal demonstrates that while overweight people can lose substantial amounts of their body weight while on the medication, the mass is regained at an average rate of nearly a kilo each month once they quit.
"Individuals using these treatments should be cognizant of the risk of rapid weight regain when the medication ends," cautioned expert Dr. Susan Jebb.
This pace of recovery suggests a reversion to original mass in about 18 months.
Analyzing Approaches
The research, which reviewed 37 of studies involving over 9,000 of patients, contrasted the outcomes of the injectable medications with other pills.
The team emphasize that individuals who shed pounds through diet and exercise generally have a more gradual creep back—perhaps 100 grams monthly—after stopping.
The Reason for the Rapid Rebound
Doctors believe the mechanism of the drugs is key to understanding the heightened regain.
GLP-1 drugs mimic a body's own chemical called GLP-1, which controls hunger.
"Sustained high doses of GLP-1 levels several times higher than normal could lead to the body to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this hormone supplement means appetite is no longer kept in check, making excessive eating a significant risk."
A Lifelong Issue?
Medical guidelines recommend the jabs for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Professionals argue that, due to the likelihood of relapse, the therapy should be considered ongoing.
This perspective is echoed by drug manufacturers, who state that the results "highlight the chronic character of obesity," similar to managing conditions like diabetes.
Patient Experiences
People who have stopped the jabs report a sudden return of cravings.
"It felt as if something that goes on and you're instantly extremely hungry," recalled one woman.
The struggle is compounded if individuals have not developed sustainable lifestyle or habit modifications during therapy.
Growing Adoption
Recent estimates suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Use is greater among women than men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Finally, clinicians caution that while these medications are effective tools for shedding pounds, they are not a permanent solution and maintained weight loss hinges on ongoing lifestyle management.
